Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$2.15
+12.0%
$17.27
$1.20
$4.10
$7.01M0.7765,409 shs65,922 shs
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
$2.42
+5.2%
$2.34
$1.72
$10.66
$6.14M1.31580,314 shs23,382 shs
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
$0.22
+2.8%
$0.27
$0.18
$1.87
$1.69M0.341.49 million shs701,845 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.80
-3.8%
$2.72
$1.75
$9.37
$6.14M1.68846,923 shs53,987 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-2.79%+14.29%-93.16%-91.79%-93.86%
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
0.00%+6.48%-4.17%+9.00%-27.44%
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
-0.05%-3.33%-3.11%-47.87%-84.54%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.25%+69.53%+63.90%+46.84%+2,367.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
3.4946 of 5 stars
3.85.00.00.03.00.81.3
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
0.8845 of 5 stars
0.03.00.00.02.31.70.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.7268 of 5 stars
0.05.00.00.02.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00
N/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
3.50
Strong Buy$11.00354.55% Upside
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$4.53M1.55N/AN/A$0.70 per share3.07
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
N/AN/AN/AN/A$5.42 per shareN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/AN/AN/AN/A$0.83 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.44N/AN/A$3.01 per share1.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-$3.08MN/A0.00N/A-85.56%-63.93%-31.42%N/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
-$7.60M-$7.00N/AN/AN/AN/A-257.47%-131.09%5/13/2025 (Estimated)
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
-$5M-$1.13N/AN/AN/A-308.97%-228.73%5/13/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)

Latest PTIX, SNOA, CPHI, and GTBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
-$0.64N/AN/AN/AN/AN/A
3/31/2025Q4 2024
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A-$0.24N/A-$0.24N/AN/A
2/5/2025Q3 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A-$0.59N/A-$0.63N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
N/AN/AN/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.22
0.79
0.26
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
N/A
1.45
1.45
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A
1.80
1.80
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49

Institutional Ownership

CompanyInstitutional Ownership
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/A
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
8.15%
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
7.97%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
17.32%
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
10.90%
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
35.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
2503.26 million15.92 millionNot Optionable
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
82.54 million1.99 millionNo Data
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
27.53 million4.71 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

China Pharma stock logo

China Pharma NYSE:CPHI

$2.15 +0.23 (+11.98%)
As of 04:00 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

GT Biopharma stock logo

GT Biopharma NASDAQ:GTBP

$2.42 +0.12 (+5.22%)
As of 04:00 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Protagenic Therapeutics stock logo

Protagenic Therapeutics NASDAQ:PTIX

$0.22 +0.01 (+2.75%)
As of 04:00 PM Eastern

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.80 -0.15 (-3.80%)
As of 04:00 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.